MatsukiyoCocokara & Co. (3088.T)
ValueMarkers Composite Index
77% below intrinsic value ($71)
MatsukiyoCocokara & Co. (3088.T) — VMCI valuation read
Composite valuation read on 3088.T: VMCI 67/100 against a Healthcare sector median of 50. The 17-point above-median print is the headline number for MatsukiyoCocokara & Co., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.
Trailing 30-day insider activity for 3088.T: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.
**Investor frame.** Value, quality, risk in three lines on 3088.T: 3088.T trades at 27.0x earnings, 50% above the Healthcare median of 18.0x; ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%); net debt to EBITDA of 2.2x is the rate-sensitivity line to watch. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.
3088.T fell 3.4% over the trailing 7 days, with a +2.2% read on a 30-day basis.
MatsukiyoCocokara & Co. operates a chain of drug stores and pharmacies in Japan. As of June 30, 2020, it operated through a network of 1,726 stores in 47 prefectures in Japan. MatsukiyoCocokara & Co. was founded in 1932 and is based in Matsudo, Japan.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.